Session 1 :Biomarkers
Biomarkers have transformed the personalized medicine and individual health advancing rapidly. Drug discovery and development, diagnosis, treatment, prognosis, and prevention, identification and validation of biomarkers play an essential role in the genome era. Biomarker Research provides fast dissemination of novel findings in the light of new knowledge. The use of biomarkers has almost become an accepted phenomenon in basic and clinical research has become so commonplace without doubt and without a question. Specific biomarkers were characterized. And they were repeatedly shown to correctly predict relevant clinical outcomes across a variety of treatments and populations. This session discusses about the advanced technologies in clinical research and biomarkers a great deal.
Session 2 :Cancer Biomarkers
Identifying a substance or a process that indicates the presence of cancer in the body is called cancer biomarkers. They are useful in establishing specific diagnoses. Cancer biomarkers also identify and determine whether tumors are of primary or metastatic origin. To distinguish researchers screen the chromosomal alterations found on cells located in the primary tumor site against those found in the secondary site. If the alterations match, the secondary tumor can be identified as metastatic; whereas if the alterations differ, the secondary tumor can be identified as a distinct primary tumor. A cancer biomarker may be a molecule secreted by a tumor or a specific response of the body to the presence of cancer. Biomarkers of cancers of prostate, breast, ovary, and lung in human serum have been reviewed, as well as those of heart disease, arthritis, asthma, and cystic fibrosis. This session further discusses the advanced developments in cancer biomarkers.
Session 3 :Molecular Biomarkers
Imaging biomarkers simply known as Molecular Biomarkers include MRI, CT, PET, used to refer to non-imaging biomarkers that have biophysical properties, which allow their measurements in biological samples such as plasma, serum, cerebrospinal fluid, bronchoalveolar lavage, biopsy. And also include nucleic acids-based biomarkers such as gene mutations or polymorphisms and quantitative gene expression analysis, peptides, proteins, lipids metabolites and other small molecules. Molecular biomarkers have been defined as biomarkers that can be discovered using basic and acceptable platforms such as genomics and proteomics. Many genomic and proteomics techniques are available for biomarker discovery and few of them are also in use. Apart from genomics and proteomics platforms biomarker assay techniques, metabolomics, lipidomics, glycomics, and secretomics are the most commonly used as techniques in identification of biomarkers. This session discusses about the latest discovery and development of molecular biomarkers.
Session 4 :Biomarkers in Clinical Research & Development
To expedite the drug development, the application of biomarkers plays a critical role in clinical research to process and produce drug therapies with safety profile maintenance at the same time. Biomarkers are in use for many decades monitoring blood pressure to lipid levels. They influence in every phase of drug development; from drug discovery to preclinical evaluations to through each phase of clinical trials and into the post-marketing studies. From traditional in vitro analyses of gene patterns, gene expression, protein expression, and metabolite quantification, to the in vivo measurement of biological processes to correlate the biomarker to clinical data is the goal of these technologies. This session discusses further development in the role of biomarkers in clinical research and development.
Session 5 :Biomarkers in Drug Discovery
Biomarkers play a significant role in drug discovery. Yet there is still a shortage of robust and valid biomarkers to accelerate the drug development process from pre-clinical through all stages of clinical studies. There is every need to introduce protein and gene arrays, high performance instrumentation such as high-field nuclear magnetic resonance and high-resolution mass spectrometers; and bioinformatics, decisions on safety and efficacy criteria can be made with higher degree of confidence. This session discusses the current definitions, biomarker categories, challenges in biological and analytical validation, along with several clinical examples. This session also discusses about the latest developments in biomarkers and drug discovery.
Session 6 :Personalized Medicine and Data Analysis
Personalized Medicine and Data Analysis tools play a key role in healthcare, which when properly exploited this data analysis and data tools and technologies can create a significant potential to improve the value and its outcomes while at the same time lowering the costs for each individual patient. Diagnostic images, genetic test results and biometric information are increasingly generated and stored in electronic health records to enhance the outcomes in personalized medicine and patient care deliveries. There is an urgent need to develop new, scalable and expandable big data infrastructure and analytical methods on scientific premise to enable healthcare providers to access knowledge for their patients yielding better decisions and outcomes. This session further discusses various emerging trends and technologies in data analyses for personalized medicine and medical care.
Session 7 :Cancer Research & Trial
Cancer research has become imminent as cancer disease is on the rise across the world. Cancer research is taken up by research institutes, corporate sectors, academia, clinical settings, and government funded organizations. Cancer research should address issues ranging from epidemiology, molecular bioscience, and clinical trials to evaluate, and compare various applications of the treatments. Clinical trials of cancer research have focused its attention towards therapies derived from biotechnology research, such as cancer immunotherapy and gene therapy. In cancer research medicine biomarkers are used in three primary ways known as diagnostic, prognostic, and predictive. This session discusses latest trends in cancer research and trial methods in clinical settings.
Session 8 :Translational Biomarkers & Diagnostics
Translational biomarkers and diagnostics play a crucial role in the outcomes and findings in clinical settings to enhance the quality of human health. Translational biomarkers and diagnostics can be applied in both preclinical and clinical setting. It should aim to translate the findings in fundamental research into medical practice and meaningful health outcomes. The characteristics for acceptable translational biomarkers and the various approaches to their selections including the latest trends and developments in translational biomarkers and diagnostics shall be discussed in this session. This session also discusses and reviews methods and requirements for qualification of translational biomarkers.
Session 9 :Functional Genomics and Cytogenetic Biomarkers
Functional genomics is a field of molecular biology that uses the vast wealth of data given by genomic and transcriptomic projects such as genome sequencing projects and RNA sequencing to describe gene and protein functions and interactions. Functional genomics focuses on the dynamic aspects such as gene transcription, translation, regulation of gene expression and protein–protein interactions, as opposed to the static aspects of the genomic information such as DNA sequence or structures. Functional genomics studies and evaluates the function of DNA at the levels of genes, RNA transcripts, and protein products. A key characteristic of functional genomics studies is their genome-wide approach rather than gene-by-gene approach. This session discusses more about functional genomics and cytogenetic biomarkers.
Session 10 :Techniques to Maximize Biomarker Identification
Biomarkers are biomolecules that identifies key indicators of biological and pathological processes; and physiological and pharmacological responses to a drug treatment. The combination of different types of technologies and statistical analysis may provide more effective methods to identify and validate new disease biomarkers in blood. Because of the high abundance of albumin and heterogeneity of plasma lipoproteins and glycoproteins, biomarkers are difficult to identify in human serum. Due to the clinical significance the identification of disease biomarkers in serum holds great promise for personalized medicine, especially for disease diagnosis and prognosis. This session discusses more techniques to maximize biomarker identification and the emerging proteomics techniques utilized in the separation of serum samples and identification of disease signatures.
Session 11 :Stem Cell and Genetic Research
Stem cell and genetics research involves with the result of the study that applies not only to the proband but also influences her lineage both in the past and in the future. Genetic studies can be done from any tissue fragment that contains DNA so that studies of surgical specimens, biopsy materials, hair, epithelium and blood samples can all be utilized for extensive genetic studies. For instance genetic studies demonstrated Thomas Jefferson's sexual relationship with his slave Sally Hemings and defined their descendants to this day. Some DNA is more medically valuable than other. Once isolated, the genetic material associated with the disorder has a good chance of yielding novel diagnostic and/or therapeutic approaches for the disorder. This session discusses more about stem cell and genetic research.
Session 12 :Microbiology Clinical Research
Microbiology Clinical Research deals with the applied research relevant to therapy and diagnostics in the fields of microbiology, infectious diseases, virology, parasitology, immunology and epidemiology. There should be a perfect collaboration between clinical colleagues and microbiologists. This approach helps the field by bridging the collaborations and increasing the visibility of the lab, helps give the collaborators information that they may find helpful in their research. Collaboration also make it possible to acquire more clinical outcome data, as well as circumvent issues such as clonality that may be encountered by performing a study in only a very small patient population or subset of organisms. This session discusses more about the problems being faced in microbiology clinical research.
Session 13 :Clinical Trials on Different Diseases
Clinical trials on different diseases are done in clinical settings. These clinical trials on different diseases require biomedical research studies on human participants. The goals of clinical trials on different diseases are to ensure scientific validity and reproducibility of the results. The resultant outcomes are to answer specific questions about biomedical behavioral interventions. Clinical trials on different diseases include newer treatments such as vaccines, drugs, dietary choices, dietary supplements etc. Clinical trials can vary in size and cost depending on the product type and development stage. These may involve a single research center or multiple research centers based in one country or in multiple countries. Notable aspect of clinical trials is to conduct only after receiving approval from the health authorities of their respective countries. This session discusses latest trends and developments in clinical trials on different diseases.
Session 14 :Bioethics and Regulatory Compliance
Bioethics includes philosophical study of the ethics of medicine and as well as areas of medical law, medical anthropology, medical sociology, health politics, health economics and even some areas of medicine itself. There are two fields of ethics that have emerged in recent decades in ethical issues in medicine. These are the fields of bioethics and of health and human rights. Bioethics is making greater inroads into academic medical contexts than medicine and medical science are making into academic philosophy. This session discusses more about bioethics, human rights, human health, clinical research and its regulatory compliance issues of nations across the world.